Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for Hr+/Her2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing
Celcuity Inc. 宣佈計劃啓動作爲Hr+/Her2-晚期乳腺癌一線治療的Gedatolisib的3期臨床試驗，並獲得約6200萬美元的債務融資